Artelo Biosciences, Inc. (ARTL) shareholders
Close on Nov 17, 2026Market cap $1.13MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Armistice Capital, LLC Joint filing with Steven Boyd (9.99%) | 235,823 | 9.99% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ARTL | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Jane Street Group, LLC | 7,371 | 0.16% | $74.30K | +5,918 | 0.00% |
| Geode Capital Management, LLC | 1,541 | 0.03% | $15.53K | New | 0.00% |
| StoneX Group Inc. | 1,378 | 0.03% | $14.69K | New | 0.00% |
| Vanguard Capital Management LLC | 1,125 | 0.02% | $11.34K | – | 0.00% |
| Tower Research Capital LLC (TRC) | 937 | 0.02% | $9.45K | +623 | 0.00% |
| Vanguard Fiduciary Trust Co | 349 | 0.01% | $3.52K | – | 0.00% |
| UBS Group AG | 312 | 0.01% | $3.14K | New | 0.00% |
| Rothschild Investment LLC | 0 | 0.00% | $2 | – | 0.00% |
| Danske Bank A/S | 0 | 0.00% | $1 | New | 0.00% |
| TD Waterhouse Canada Inc. | 0 | 0.00% | $2 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10 | 0M | 0.3% | 5 / 2 | 0 / 5 | 0M | 0M |
| Q1 2026 | 11 | 0M | 0.1% | 7 / 1 | 0 / 5 | 0M | 0M |
| Q4 2025 | 10 | 0M | 0.1% | 6 / 2 | 0 / 5 | 0M | 0M |
| Q3 2025 | 9 | 0M | 0.0% | 3 / 4 | 0 / 3 | 0M | 0M |
| Q2 2025 | 9 | 0M | 0.0% | 9 / 0 | 0 / 0 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Gregory D. Gorgas | Pres, CEO, CFO, Treas & Secr, Director | 273,076 | 5.94% | Feb 2, 2026 |
| Mark Edward Spring | Chief Financial Officer | – | – | Feb 2, 2026 |
| Tamara A. Favorito | Director | – | – | Jul 21, 2026 |
| Robert Martin Emanuele | Director | 12,500 | 0.27% | Jul 21, 2026 |
| Steven Kelly | Director | 12,500 | 0.27% | Jul 21, 2026 |
| Douglas Blayney | Director | 12,500 | 0.27% | Jul 21, 2026 |
| Gregory Reyes | Director | – | – | Jul 21, 2026 |
| Connie Matsui | Director | 56,667 | 1.23% | Jul 21, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Gregory D. Gorgas Pres, CEO, CFO, Treas & Secr, Director | Aug 12, 2022 | Buy | +1,200 | $4.00 | $4.80K | 2,400 |
| Gregory D. Gorgas Pres, CEO, CFO, Treas & Secr, Director | Aug 11, 2022 | Buy | +1,200 | $4.03 | $4.84K | 1,200 |
| Gregory D. Gorgas Pres, CEO, CFO, Treas & Secr, Director | Apr 16, 2021 | Buy | +8,500 | $1.15 | $9.78K | 270,676 |
| Gregory D. Gorgas Pres, CEO, CFO, Treas & Secr, Director | May 15, 2020 | Buy | +4,200 | $1.21 | $5.08K | 262,176 |
| Gregory D. Gorgas Pres, CEO, CFO, Treas & Secr, Director | May 4, 2020 | Buy | +4,167 | $1.20 | $5.00K | 257,976 |
| Connie Matsui Director | May 4, 2020 | Buy | +41,667 | $1.20 | $50.00K | 56,667 |
| Gregory D. Gorgas Pres, CEO, CFO, Treas & Secr, Director | Nov 4, 2019 | Buy | +2,400 | $2.21 | $5.30K | 253,809 |
| Gregory D. Gorgas Pres, CEO, CFO, Treas & Secr, Director | Nov 1, 2019 | Buy | +2,500 | $2.28 | $5.70K | 251,409 |
| Gregory D. Gorgas Pres, CEO, CFO, Treas & Secr, Director | Oct 31, 2019 | Buy | +2,500 | $1.95 | $4.88K | 248,909 |
| Gregory D. Gorgas Pres, CEO, CFO, Treas & Secr, Director | Oct 30, 2019 | Buy | +2,600 | $1.99 | $5.17K | 246,409 |
| Gregory D. Gorgas Pres, CEO, CFO, Treas & Secr, Director | Oct 15, 2019 | Buy | +2,600 | $2.05 | $5.33K | 243,809 |
| Gregory D. Gorgas Pres, CEO, CFO, Treas & Secr, Director | Oct 11, 2019 | Buy | +2,700 | $1.96 | $5.29K | 241,209 |
| Peter Michael O'Brien 10% owner | Sep 4, 2019 | Other | −17,500 | – | – | 7,500 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Artelo Biosciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 72,699 shares on Sep 24, 2026 over the last 90 days.
See a number that looks wrong?